Abbott India appoints Prithwish K Banerji as Commercial Director - Women’s Health, Metabolics and International Business
Prithwish has close to 28 years of experience in a Commercial role
Prithwish has close to 28 years of experience in a Commercial role
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Final decision from the European Commission is anticipated within the coming months
Subscribe To Our Newsletter & Stay Updated